One email when new issuers, new metrics and new articles land. Double opt-in, zero spam, one-click unsubscribe.
L&G Pharma Breakthrough UCITS ETF tracks the issuer-declared index: Solactive Pharma Breakthrough Value Index Net TR USD. The declared annual cost (TER) is 0.49%, plus 0.13% in transaction costs estimated by the issuer in the KID. Replication is full physical replication (the KID declares buying every index constituent); income is accumulated and reinvested in the fund. The fund has assets of about 18 million euro, was launched on 23 January 2018 and is domiciled in Ireland.
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. The Fund is passively managed and aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”), before the deduction of fees and expenses. The Index is designed to provide exposure to biotechnology companies worldwide that are actively engaged in the research, development and/or manufacturing of orphan drugs, in accordance with its methodology.
Keep reading the KID section ▾
The Fund seeks to achieve its investment objective by investing primarily in equity securities that, as far as possible and practicable, make up the Index in similar proportions to their weightings in the Index. Where it is not possible or practicable to invest directly in all of the constituents of the Index, the Fund may also invest in equity related securities and instruments that are not constituents of the Index but have similar risk and performance characteristics, and may use financial derivative instruments for efficient portfolio management or to assist in tracking the performance of the Index. The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement. This Share Class does not intend to pay dividends. Any income which may result from the Fund's investments will be re-invested into the Fund. Shares in this Share Class (the "Shares") are denominated in USD and can be bought and sold on stock exchanges by ordinary investors using an intermediary (e.g. a stockbroker). In normal circumstances, only Authorised Participants may buy and sell Shares directly with the Company. Authorised Participants may redeem their Shares on demand in accordance with the "Dealing Timetable" published on http://www.lgim.com.
The depositary of the Fund is the Bank of New York Mellon SA/NV, Dublin Branch. Further information about the Fund and the share class can be obtained from the Company's prospectus and the annual and semi-annual reports, which are available, in addition to the latest prices for the share class and details of any other share classes, free of charge at: www.lgim.com.
Intended Retail Investor:The Fund is designed for investors looking to grow their money in an investment which can form part of their existing savings portfolio. Although investors can take their money out at any time, the Fund may not be appropriate for those who plan to withdraw their money within five years. The Fund is not designed for investors who cannot afford more than a minimal loss of their investment.
| From the peak of | Trough | Depth | Back to break-even | Days underwater |
|---|---|---|---|---|
| 11 Feb 2021 | 19 Apr 2024 | -34.19% | 17 Nov 2025 | 1,740 |
| 19 Feb 2020 | 23 Mar 2020 | -27.35% | 27 Apr 2020 | 68 |
| 28 Sept 2018 | 24 Dec 2018 | -22.51% | 21 Jan 2020 | 480 |
| 26 Jan 2018 | 06 Apr 2018 | -11.32% | 17 Jul 2018 | 172 |
| 07 Jul 2026 | 03 Aug 2026 | -10.43% | 19 Aug 2026 | 43 |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sept | Oct | Nov | Dec | Year | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.3 | 1.5 | -3.2 | 2.6 | 0.1 | 8.1 | -5.0 | 9.7 | -0.4 | 13.5 | |||
| 2025 | 4.3 | 5.3 | -3.6 | 0.5 | 0.5 | -0.8 | 5.9 | 6.4 | 6.0 | 5.1 | 4.4 | -1.7 | 36.8 |
| 2024 | -5.2 | -1.1 | -0.2 | -5.2 | 3.4 | 1.9 | 6.4 | 6.8 | -3.1 | -1.1 | 0.5 | -6.8 | -4.8 |
| 2023 | 4.0 | -4.9 | -2.9 | 3.5 | -3.8 | -3.1 | 3.3 | -2.4 | -6.1 | -7.2 | 6.5 | 3.7 | -10.3 |
| 2022 | -6.0 | -1.1 | 2.3 | -5.9 | -4.0 | 1.1 | 1.8 | -3.2 | -4.2 | 3.1 | 8.8 | 0.7 | -7.3 |
| 2021 | -0.2 | -3.0 | -2.5 | 1.7 | 0.2 | 4.8 | -3.1 | 3.9 | -3.5 | 0.7 | -4.1 | 1.7 | -3.8 |
| 2020 | 1.2 | -2.0 | -8.0 | 17.9 | 6.8 | 0.8 | 0.8 | 4.2 | -1.5 | -6.2 | 7.4 | 5.5 | 27.1 |
| 2019 | 7.7 | 5.0 | -1.5 | -5.5 | -5.3 | 7.6 | -3.0 | -2.5 | -5.3 | 8.8 | 10.9 | -2.7 | 12.7 |
| 2018 | -5.3 | -1.2 | 0.0 | 4.6 | 0.4 | 5.8 | 6.2 | 0.2 | -14.5 | 4.7 | -8.3 | -7.9 |
| Year | Fund | Index | Difference |
|---|---|---|---|
| 2025 | +36.81% | +37.28% | -0.47% |
| 2024 | -4.81% | -4.29% | -0.52% |
| 2023 | -10.26% | -9.94% | -0.33% |
| 2022 | -7.26% | -6.86% | -0.41% |
| 2021 | -3.85% | -3.57% | -0.28% |
| 2020 | +27.09% | +28.09% | -1.00% |
| 2019 | +12.67% | +13.45% | -0.78% |
| Last year | Last 3 years | Last 5 years | Full history | |
|---|---|---|---|---|
| Volatility (ann.) | 17.97% | 16.60% | 17.03% | 18.60% |
| Max drawdown | -11.22% | -19.96% | -28.32% | -28.90% |
| Sharpe | 1.19 | 0.46 | 0.13 | 0.31 |
| Sortino | 1.76 | 0.65 | 0.18 | 0.44 |
According to the official lists published by the brokers (downloaded and cross-checked by us), these share classes of the fund appear tradable with zero fees:
IE00BF0H7608Official lists verified on 3 September 2026. We record published terms — this is neither an invitation to open accounts nor a recommendation: lists change, the broker’s documents prevail. Trade Republic, Scalable Capital and Trading 212 publish no per-ISIN lists and don’t appear here.
| Exchange | Ticker | Trading since |
|---|---|---|
| Borsa Italiana (ETFplus) | BIOT | 23 Feb 2018 |
| Börse Düsseldorf | ETLI | 20 Apr 2020 |
| Börse Frankfurt | ETLI | 20 Apr 2020 |
| Börse Hamburg | ETLI | 20 Apr 2020 |
| Börse Hannover | ETLI | 9 Dec 2024 |
| Börse München / gettex | ETLI | 12 Sept 2019 |
| Börse Stuttgart | ETLI | 20 Apr 2020 |
| Euronext Amsterdam | BIOT | 1 Feb 2018 |
| Tradegate Exchange | ETLI | 20 Apr 2020 |
| Xetra (Deutsche Börse) | ETLI | 20 Apr 2020 |